A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Inclusion Criteria:

• Age 18 to 75 years, inclusive, at the start of the run-in period

• AD diagnosed by the Hanifin/Rajka criteria and that has been present for at least 1year at screening

• Moderate to severe AD as graded by the Rajka/Langeland criteria at screening

• History of inadequate response to a >/= 1 month (within the 3 months prior to thescreening visit) treatment regimen of at least daily TCS and regular emollient fortreatment of AD

• EASI score >/= 14 at screening

• IGA score >/= 3

• AD involvement of >/= 10% body surface area

• Pruritus Visual Analog Scale score >/= 3

Exclusion Criteria:

• Past and/or current use of any anti-IL-13 or anti-IL-4/IL-13 therapy, includinglebrikizumab

• Use of an investigational agent within 4 weeks prior to screening or within 5half-lives of the investigational agent, whichever is longer

• Evidence of other skin conditions, including, but not limited to, T-cell lymphoma orallergic contact dermatitis

• History of a severe allergic reaction or anaphylactic reaction to a biologic agent orknown hypersensitivity to any component of the lebrikizumab injection

• Use of any complementary, alternative, or homeopathic medicines including, but notlimited to, phytotherapies, traditional or non-traditional herbal medications,essential fatty acids, or acupuncture within 7 days prior to the run-in period or needfor such medications during the study

• Evidence of other skin conditions; including, but not limited to, T-cell lymphoma orallergic contact dermatitis

• Evidence of, or ongoing treatment (including topical antibiotics) for active skininfection at screening

• Other recent infections meeting protocol criteria

• Active tuberculosis requiring treatment within the 12 months prior to Visit 1

• Evidence of acute or chronic hepatitis or known liver cirrhosis

• Known immunodeficiency, including HIV infection

• Use of a topical calcineurin inhibitor (TCI) at the time of screening, unless thepatient is willing to stop TCI use during the study (including the run-in period) and,in the investigator's opinion, it is safe to do so

• Clinically significant abnormality on screening ECG or laboratory tests

• Known current malignancy or current evaluation for a potential malignancy, includingbasal or squamous cell carcinoma of the skin or carcinoma in situ

• History of malignancy within 5 years prior to screening, except for appropriatelytreated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterinecancer